David Einhorn - DME Capital Management,
Holding/activity history for Roivant Sciences Ltd (ROIV)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 2,152,669 | 1.87 | Add 4.03% | 0.07 | $27.70 | $59,628,931 | SEC |
| 2025 Q4 | 2,069,309 | 1.58 | Reduce 9.06% | 0.12 | $21.70 | $44,904,005 | SEC |
| 2025 Q3 | 2,275,529 | 1.35 | Reduce 50.00% | 1.11 | $15.13 | $34,428,754 | SEC |
| 2025 Q2 | 4,551,057 | 2.21 | Reduce 16.36% | 0.45 | $11.27 | $51,290,412 | SEC |
| 2025 Q1 | 5,441,167 | 2.78 | Add 3.23% | 0.09 | $10.09 | $54,901,375 | SEC |
| 2024 Q4 | 5,271,067 | 3.21 | Reduce 0.70% | 0.02 | $11.83 | $62,356,723 | SEC |
| 2024 Q3 | 5,308,040 | 2.55 | Add 10.33% | 0.24 | $11.54 | $61,254,781 | SEC |
| 2024 Q2 | 4,810,960 | 2.49 | Add 14.81% | 0.32 | $10.57 | $50,851,847 | SEC |
| 2024 Q1 | 4,190,490 | 2.02 | $10.54 | $44,167,765 | SEC |